Particularly committed to the issue of public health, Fedez has launched a new alarm on social media. This time the problem concerns the shortage of a fundamental drug for patients who, like him, suffer from pancreatic diseases. The medicine (whose name is Creon or Creonipe) has been unobtainable for several months, but in recent weeks reports from patients have increased.
Fedez and the need for pancreatic enzymes
Unlike many drugs that also have an equivalent medicine, this is not the case for this one in particular. And therefore there are no alternatives for patients. «Being I was pancreatic surgery, and having had almost the entire pancreas removed,” Fedez explained in a story Instagram«like all people like me I need to take pancreatic enzymes to be able to assimilate food. And we’re having problems.”
Reporting of sick people to Fedez
Like him, other patients in the same conditions are also having them. «I’m receiving a lot of emails», continued the rapper, because «it seems that pancreatic enzymes can no longer be found in pharmacies. I had a small supply but I’m running out of them and they haven’t been available for a month now.”
The response of the Ministry of Health
Fedez then explained that apparently there is only one company that produces the drug, and who is unable to meet the request. Then the rapper launched an appeal: «It seems that the issue is bigger than it seemed at the beginning, and that the medicine is no longer available in Northern Italy. Send us your emails, so we will contact AIFA».
Soon, a response arrived from the Ministry of Health. The ministry underlines that the matter, «independent of Aifa’s regulatory activities», is «followed with great attention, all relevant activities aimed at guaranteeing the therapeutic continuity of patients have been implemented”.
The reason for the shortage
The reason for the shortage, the ministry clarifies, is that «to date the only manufacturing company (Viatris Italia Srl) has communicated the impossibility of satisfying demand due to excess demand. However, the Agency allows healthcare facilities to import similar medicines authorized abroad.” This “in the event that the structures themselves encounter discontinuities in supply, at the level of the distribution networks to which they have access”. Furthermore, the ministry note concludes, «pharmacies that cannot find the product in the usual distribution channels can place a direct order with the owner via the appropriate Customer Service service».
Viatris, for its part, has made it known that the medicine is not produced in-house. And that he «received information from the company producing the drug, Abbott, of some difficulties in the supply of Creon (pancrelipase). The supply difficulties are due to the high demand globally.” However, the company clarifies that it is working “to mitigate supply difficulties and reduce the impact on patients”.
iO Donna © ALL RIGHTS RESERVED
2024-01-29 08:39:15
#Fedezs #alarm #pancreatic #enzymes #Woman
